LXEO · Company research
Lexeo Therapeutics, Inc. Common Stock (LXEO): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
21records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Lexeo Therapeutics to Host Educational Event Focused on Clinical Endpoints and Outcome Measures in PKP2-ACM | Lexeo Therapeutics announced an educational investor event on October 21, 2026, featuring discussions on clinical endpoints and outcome measures for PKP2-arrhythmogenic cardiomyopathy (PKP2-ACM). The event will include Lexeo's Chief Medical Officer and a specialist from Cleveland Clinic discussing the clinical significance of key assessments and treatment response evaluation for this genetic heart disease. | View source ↗ | GlobeNewswire Inc. | Oct 19, 2026 | bullish | 1 | 1 |
| JPMorgan reports ownership above 5% in Lexeo Therapeutics (LXEO). - Stock Titan | JPMorgan reports ownership above 5% in Lexeo Therapeutics (LXEO). Stock Titan | View source ↗ | Stock Titan | Oct 13, 2026 | neutral | 0 | 0.6 |
| Lexeo Therapeutics, Inc. (LXEO) Stock Price, News, Quote & History - Yahoo! Finance Canada | Lexeo Therapeutics, Inc. (LXEO) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 9, 2026 | neutral | 0 | 0.6 |
| Lexeo Therapeutics to Participate in the Chardan Healthcare Conference | Lexeo Therapeutics, a clinical-stage biotech company, announced it will participate in a fireside chat at Chardan's 10th Annual Healthcare Conference on October 20, 2026. The company is focused on developing genetic disease treatments, including LX2006 for Friedreich ataxia and LX2020 for arrhythmogenic cardiomyopathy. | View source ↗ | GlobeNewswire Inc. | Oct 8, 2026 | bullish | 1 | 1 |
| Lexeo Therapeutics to Participate in the Chardan Healthcare Conference | Lexeo Therapeutics, a clinical-stage biotech company, announced it will participate in a fireside chat at Chardan's 10th Annual Healthcare Conference on October 20, 2026. The company is focused on developing genetic disease treatments, including LX2006 for Friedreich ataxia and LX2020 for arrhythmogenic cardiomyopathy. | View source ↗ | GlobeNewswire Inc. | Oct 8, 2026 | bullish | 1 | 1 |
| A healthcare conference fireside chat will stream live Oct. 20, featuring Lexeo Therapeutics. - Stock Titan | A healthcare conference fireside chat will stream live Oct. 20, featuring Lexeo Therapeutics. Stock Titan | View source ↗ | Stock Titan | Oct 8, 2026 | neutral | 0 | 0.6 |
| Lexeo Therapeutics Inc (LXEO-Q) Stock Price and News - The Globe and Mail | Lexeo Therapeutics Inc (LXEO-Q) Stock Price and News The Globe and Mail | View source ↗ | The Globe and Mail | Oct 1, 2026 | neutral | 0 | 0.6 |
| Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS) | Lexeo Therapeutics announced that its abstract for LX2006, an AAV-based gene therapy for Friedreich ataxia, has been accepted for oral presentation at the MDS 2026 Congress in Seoul. The presentation will highlight early stabilization or improvement in mFARS scores in LX2006-treated participants compared to propensity-matched controls, along with new subscore analyses. LX2006 has received multiple FDA designations including Breakthrough Therapy and Orphan Drug status. | View source ↗ | GlobeNewswire Inc. | Oct 1, 2026 | bullish | 1 | 1 |
| Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS) | Lexeo Therapeutics announced that its abstract for LX2006, an AAV-based gene therapy for Friedreich ataxia, has been accepted for oral presentation at the MDS 2026 Congress in Seoul. The presentation will highlight early stabilization or improvement in mFARS scores in LX2006-treated participants compared to propensity-matched controls, along with new subscore analyses. LX2006 has received multiple FDA designations including Breakthrough Therapy and Orphan Drug status. | View source ↗ | GlobeNewswire Inc. | Oct 1, 2026 | bullish | 1 | 1 |
| Early data found stable or improved neurologic scores among gene therapy participants. New analyses are due Oct. 7. - Stock Titan | Early data found stable or improved neurologic scores among gene therapy participants. New analyses are due Oct. 7. Stock Titan | View source ↗ | Stock Titan | Oct 1, 2026 | neutral | 0 | 0.6 |
| At $3.39 a share, Lexeo Therapeutics (LXEO) grants its CFO 54,750 stock options. - Stock Titan | At $3.39 a share, Lexeo Therapeutics (LXEO) grants its CFO 54,750 stock options. Stock Titan | View source ↗ | Stock Titan | Sep 28, 2026 | neutral | 0 | 0.6 |
| Lexeo Therapeutics (LXEO) Stock Analysis Report | Financials & Insights - Benzinga | Lexeo Therapeutics (LXEO) Stock Analysis Report | Financials & Insights Benzinga | View source ↗ | Benzinga | Sep 27, 2026 | neutral | 0 | 0.6 |
| $LXEO stock is down 14% today. Here's what we see in our data. - Quiver Quantitative | $LXEO stock is down 14% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Sep 23, 2026 | neutral | 0 | 0.6 |
| $LXEO stock is down 14% today. Here's what we see in our data. - Quiver Quantitative | $LXEO stock is down 14% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Sep 23, 2026 | neutral | 0 | 0.6 |
| Four therapies for a missing brain protein may join Lexeo - Stock Titan | Four therapies for a missing brain protein may join Lexeo Stock Titan | View source ↗ | Stock Titan | Sep 22, 2026 | neutral | 0 | 0.6 |
| What Makes Lexeo Therapeutics (LXEO) One of The Best Stocks Under $10 That Could Triple - Yahoo Finance | What Makes Lexeo Therapeutics (LXEO) One of The Best Stocks Under $10 That Could Triple Yahoo Finance | View source ↗ | Yahoo Finance | Jul 15, 2026 | neutral | 0 | 0.6 |
| Is Lexeo Therapeutics, Inc. (LXEO) Stock Still a Gene Therapy Opportunity After Analyst Valuation Update? - Yahoo Finance | Is Lexeo Therapeutics, Inc. (LXEO) Stock Still a Gene Therapy Opportunity After Analyst Valuation Update? Yahoo Finance | View source ↗ | Yahoo Finance | Jul 2, 2026 | neutral | 0 | 0.6 |
| LXEO Forecast — Price Target — Prediction for 2027 - TradingView | LXEO Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 26, 2026 | neutral | 0 | 0.6 |
| Lexeo Therapeutics’s LX2006 Has A Viable Regulatory Pathway And Timeline (NASDAQ:LXEO) - Seeking Alpha | Lexeo Therapeutics’s LX2006 Has A Viable Regulatory Pathway And Timeline (NASDAQ:LXEO) Seeking Alpha | View source ↗ | Seeking Alpha | Jun 22, 2026 | neutral | 0 | 0.6 |
| Lexeo Therapeutics, Inc. (LXEO) Stock Price, News, Quote & History - Yahoo! Finance Canada | Lexeo Therapeutics, Inc. (LXEO) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Jan 10, 2026 | neutral | 0 | 0.6 |
| LXEO Stock Price and Chart — NASDAQ:LXEO - TradingView | LXEO Stock Price and Chart — NASDAQ:LXEO TradingView | View source ↗ | TradingView | Nov 25, 2025 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.